Stock Events

Stock Events

Scancell 

$1.4100
26
+$0.01+0.71%Wednesday 17:34

Statistics

Day High
0.141
Day Low
0.141
52W High
3.35
52W Low
0.141
Volume
15,000
Avg. Volume
640
Mkt Cap
1.46B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 4Expected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q3 2026
Next
-12.02
-8.12
-4.21
-0.3
Expected EPS
-9.012912848589998
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-24.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCNLF. It's not an investment recommendation.
Lloyds Banking Group
8
LLOY.LSE
Barclays
7
BARC.LSE
Greencoat UK Wind
7
UKW.LSE
Rolls-Royce
6
RR.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology, similar to Scancell's focus on novel immunotherapies, making them direct competitors in the vaccine and therapeutic space.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes in the development of novel immunotherapies for cancer and infectious diseases, directly aligning with Scancell's research focus.
Novavax
NVAX
Mkt Cap1.66B
Novavax is involved in the development of vaccines for infectious diseases, competing with Scancell's infectious disease vaccine programs.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that develops drugs for infectious diseases, directly competing with Scancell's therapeutic development.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on human therapeutics, including treatments for cancer and inflammation, overlapping with Scancell's therapeutic areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer develops vaccines and therapeutics for various diseases, competing with Scancell in the broader pharmaceutical and biotech industry.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and therapeutics, similar to Scancell's focus areas.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is involved in the development of vaccines and cancer treatments, making it a competitor in Scancell's key research areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies, a technology that competes with Scancell's immunotherapy approaches.
Merck
MRK
Mkt Cap368.89B
Merck & Co. develops vaccines and cancer immunotherapies, directly competing with Scancell's product development pipeline.

About

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Show More
CEO
Phillip John L'Huillier
Employees
60
Country
United Kingdom
ISIN
GB00BX8KRW34
WKN
000A42NWM

Listings

LSE
GB
SCLP.LSE
OTCM
US
SCNLF
F
DE
SCP0.F
OTC Link
US
SCNLD

0 Comments

Share your thoughts

FAQs

What is Scancell stock price today?▼
The current price of SCNLF is $1.41 USD — it has increased by +0.71% in the past 24 hours. Watch Scancell stock price performance more closely on the chart.
What is Scancell stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Scancell stocks are traded under the ticker SCNLF.
Is Scancell stock price growing?▼
SCNLF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Scancell has showed a +18.39% increase.
What is Scancell market cap?▼
Today Scancell has the market capitalization of 1.46B
When is the next Scancell earnings date?▼
Scancell is going to release the next earnings report on February 4, 2027.
What were Scancell earnings last quarter?▼
SCNLF earnings for the last quarter are -0.16 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scancell revenue for the last year?▼
Scancell revenue for the last year amounts to 0 USD.
What is Scancell net income for the last year?▼
SCNLF net income for the last year is -24.1M USD.
How many employees does Scancell have?▼
As of November 5, 2026, the company has 60 employees.
In which sector is Scancell located?▼
Scancell operates in the Health & Wellness sector.
When did Scancell complete a stock split?▼
The last stock split for Scancell was on October 21, 2026 with a ratio of 1:10.
Where is Scancell headquartered?▼
Scancell is headquartered in Oxford, United Kingdom.